Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 3/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27299461 | 0.92 | TLR2 (0.35) | TLR2 | |
| SCHEMBL27299109 | 0.92 | TLR2 (0.33) | TLR2 | |
| SCHEMBL27299105 | 0.87 | TLR2 (0.34) | TLR2CTSK | |
| SCHEMBL30977743 | 0.87 | TLR2 (0.33) | TLR2 | |
| SCHEMBL27299704 | 0.86 | CTSK (0.35) | TLR2CTSK | |
| SCHEMBL27301072 | 0.86 | CTSK (0.37) | TLR2CTSK | |
| SCHEMBL27299472 | 0.86 | CTSK (0.35) | CTSK | |
| SCHEMBL30977730 | 0.85 | KLK7 (0.32) | TLR2 | |
| SCHEMBL27299110 | 0.85 | CTSK (0.33) | CTSK | |
| SCHEMBL27299467 | 0.85 | TLR2 (0.32) | TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638417-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | Nanovation Therapeutics Inc. (CA) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025035202-A1 | IONIZABLE LIPIDS COMPRISING MACROCYCLIC RINGS FOR THE DELIVERY OF THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| US-20240398977-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-12-05 | — | — | US | disclosed |
| US-12121591-B2 | Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents | NANOVATION THERAPEUTICS INC. (CA) | 2024-10-22 | — | — | US | disclosed |
| US-20240261430-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-08-08 | — | — | US | disclosed |
| WO-2024130421-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024130421-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12121591-B2 | Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents | SLC43A1, NSUN3, NSUN2 | TLR2 3615/4885CTSK 3564/4885 |
| US-20240261430-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | SLC43A1, NSUN3, NSUN2 | TLR2 3615/4885CTSK 3564/4885 |
| US-20240398977-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | SLC43A1, NSUN3, NSUN2 | TLR2 3615/4885CTSK 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.